Results 161 to 170 of about 33,569 (238)

Olaparib Monotherapy or in Combination with Abiraterone for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) and a BRCA Mutation. [PDF]

Target Oncol
Saad F, Armstrong AJ, Shore N, George DJ, Oya M, Sugimoto M, McKay RR, Hussain M, Clarke NW.   +8 more
europepmc   +1 more source

Non-BRCA Gene Mutation [PDF]

, 2020
openaire   +1 more source

Dichotomous assessments of homologous recombination deficiency are insufficient predictive biomarkers for the PARP inhibitor treatment of ovarian cancer

Clinical and Translational Medicine, Volume 16, Issue 11, November 2026.
Jesenia M. Perez, Justin Hwang, Britt K. Erickson, Stefani N. Thomas   +3 more
wiley   +1 more source

BRCA Mutation Testing in Men With Metastatic Castration-Resistant Prostate Cancer: Practical Guidance for Australian Clinical Practice. [PDF]

Asia Pac J Clin Oncol
Azad AA, Gurney H, Campbell A, Goh JC, Rathi V.   +4 more
europepmc   +1 more source

Decision aids for female BRCA mutation carriers: a scoping review. [PDF]

BMJ Open
McGarrigle SA, Prizeman G, Spillane C, Byrne N, Drury A, Polus M, Mockler D, Connolly EM, Brady AM, Hanhauser YP.   +9 more
europepmc   +1 more source

Olaparib and somatic BRCA mutations

Oncotarget, 2017
George, A, Banerjee, S, Kaye, S
openaire   +2 more sources

The Association Between Location of BRCA Mutation and Efficacy of PARP Inhibitor as a Frontline Maintenance Therapy in Advanced Epithelial Ovarian Cancer. [PDF]

Cancers (Basel)
Kim JH, Kim SI, Kim ET, Ha HI, Lee DE, Lee YJ, Lee JY, Kim S, Kim SW, Kim YT, Park SY, Lim MC, Nam EJ.   +12 more
europepmc   +1 more source

Case Report: Could genetic factors influence the outcomes of first-line enfortumab vedotin plus pembrolizumab therapy in patients with metastatic urothelial carcinoma? Two cases of patients harbouring a BRCA mutation. [PDF]

Front Oncol
Salfi G, Clerici CMA, Pecoraro G, Pedrani M, Puglisi M, Tortola L, Pereira Mestre R, Vogl U, Colombo I, Barizzi J, Frattini M, Graffeo R, Rizzo S, Gallina A, Monni F, Fossati N, Gillessen S, Turco F.   +17 more
europepmc   +1 more source

Cost-utility analysis of olaparib assisted targeted therapy for BRCA mutation HER2-negative early breast cancer in China and in the United States. [PDF]

Cost Eff Resour Alloc
Xu C, Zhuang J, Shen J, Sun H, Cai J, Wei X.   +5 more
europepmc   +1 more source

BRCA-Mutated Ovarian Carcinoma [PDF]

, 2020
openaire   +1 more source